Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration.
disease activity
inter-country comparison
pain
patient-reported outcome (PRO)
rheumatoid arthritis
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
02 11 2022
02 11 2022
Historique:
received:
21
09
2021
accepted:
29
01
2022
pubmed:
10
2
2022
medline:
4
11
2022
entrez:
9
2
2022
Statut:
ppublish
Résumé
To investigate whether patient-reported outcomes vary across countries and are influenced by cultural/contextual factors. Specifically, we aimed to assess inter-country differences in tender joint count (TJC), pain and patient's global health assessment (PGA), and their impact on disease activity (DAS28-CRP) in RA patients from five Nordic countries. We collected data (baseline, 3- and 12-months) from rheumatology registers in the five countries comprising RA patients starting a first ever MTX or a first ever TNF inhibitor (TNFi). In order to assess the role of context (=country), we separately modelled TJC, pain and PGA as functions of objective variables (CRP, swollen joint count, age, sex, calendar period and disease duration) with linear models. Analyses were performed at each time point and for both treatments. We further assessed the impact of inter-country differences on DAS28-CRP. A total of 27 645 RA patients started MTX and 19 733 started a TNFi. Crude inter-country differences at MTX start amounted to up to 4 points (28 points scale) for TJC, 10 and 27 points (0-100 scale) for pain and PGA, respectively. Corresponding numbers at TNFi start were 3 (TJC), 27 (pain) and 24 (PGA) points. All differences were reduced at 3- and 12-months, and attenuated when adjusting for the objective variables. The variation in predicted DAS28-CRP across countries amounted to <0.5 units. Inter-country differences in TJC, pain and PGA are greater than expected based on differences in objective measures, but have a small clinical impact on DAS28-CRP across countries.
Identifiants
pubmed: 35139178
pii: 6525251
doi: 10.1093/rheumatology/keac081
pmc: PMC9629415
doi:
Substances chimiques
Antirheumatic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4286-4296Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Références
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S188-94
pubmed: 16273806
Ann Rheum Dis. 2017 Jan;76(1):17-28
pubmed: 27697765
Clin Epidemiol. 2017 Nov 29;9:627-632
pubmed: 29238225
Pain Physician. 2018 Nov;21(6):541-558
pubmed: 30508984
Rheumatology (Oxford). 2017 May 1;56(5):725-735
pubmed: 28064209
Clin Epidemiol. 2016 Oct 25;8:737-742
pubmed: 27822121
Ann Rheum Dis. 2011 Mar;70(3):516-9
pubmed: 21081525
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-147-9
pubmed: 25365105
Scand J Rheumatol. 2017 Sep;46(5):359-363
pubmed: 27931158
Pain Med. 2012 Apr;13(4):522-40
pubmed: 22390201
Rev Pain. 2008 Mar;1(2):6-9
pubmed: 26525084
Ann Rheum Dis. 2009 Jun;68(6):954-60
pubmed: 18490431
RMD Open. 2018 Apr 12;4(1):e000655
pubmed: 29682328
J Rheumatol. 2020 Oct 1;47(10):1575-1581
pubmed: 32007931
J Pain. 2007 Apr;8(4):363-9
pubmed: 17275416
J Pain. 2007 Sep;8(9):730-6
pubmed: 17569595